PAMU
RPRX icon

Pictet Asset Management (UK)’s Royalty Pharma RPRX Stock Holding History

Pictet Asset Management (UK)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$12.5M Sell
305,245
-8,792
-3% -$374K 0.01% 634
2021
Q1 		$13.7M Sell
314,037
-19,875
-6% -$942K 0.02% 585
2020
Q4 		$16.7M Buy
+333,912
New +$14.2M 0.02% 515

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Pictet Asset Management (UK)'s RPRX Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Royalty Pharma (RPRX) stake by 2.8% in Q2 2021, selling an estimated $374K and leaving 305,245 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #634.

Pictet Asset Management (UK) first reported a position in RPRX in Q4 2020 and has held it in 3 quarters since. The position peaked at $16.7M in Q4 2020. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

  • Pictet Asset Management (UK) held 305,245 shares of Royalty Pharma worth $12.5M as of Q2 2021.
  • Pictet Asset Management (UK) sold 8,792 Royalty Pharma shares in Q2 2021, an estimated $374K.
  • Royalty Pharma made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #634 holding.
  • Pictet Asset Management (UK) first reported a position in Royalty Pharma in Q4 2020 and has held it in 3 quarters since.
  • Pictet Asset Management (UK)'s Royalty Pharma position peaked at $16.7M in Q4 2020.
  • 236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.